Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Lapatinib is a HER1 and HER2 tyrosine kinase inhibitor (TKI) approved in second line treatment of advanced or metastatic breast cancer following progression on trastuzumab-containing therapy. Biomarkers for activity of lapatinib and other TKIs are lacking. Formalin-fixed, paraffin-embedded primary t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Duchnowska, Renata, Sperinde, Jeff, Czartoryska-Arłukowicz, Bogumiła, Myśliwiec, Paulina, Winslow, John, Radecka, Barbara, Petropoulos, Christos, Demlova, Regina, Orlikowska, Marlena, Kowalczyk, Anna, Lang, Istvan, Ziółkowska, Barbara, Dębska-Szmich, Sylwia, Merdalska, Monika, Grela-Wojewoda, Aleksandra, Żawrocki, Anton, Biernat, Wojciech, Huang, Weidong, Jassem, Jacek
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732794/
https://ncbi.nlm.nih.gov/pubmed/29262628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados